Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonafarnib - Sentynl Therapeutics

Drug Profile

Lonafarnib - Sentynl Therapeutics

Alternative Names: EBP 994; MK-6336; Sarasar; SCH-066336; SCH-66336; Zokinvy

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer AnGes; Eiger BioPharmaceuticals, Inc.; Merck & Co; Schering-Plough
  • Class Amides; Antineoplastics; Antivirals; Benzene derivatives; Halogenated hydrocarbons; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progeria; Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Progeria
  • Phase III Hepatitis D
  • Discontinued Breast cancer; Cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 03 May 2024 Sentynl Therapeutics acquires lonafarnib from Eiger BioPharmaceuticals
  • 18 Jan 2024 Registered for Progeria in Japan (PO)
  • 31 Dec 2023 Eiger BioPharmaceuticals applies for named patient program approvals in Spain and United kingdom
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top